bemrist breezhaler
novartis europharm limited - indacaterol, mometasone furoate - asthma - drugs for obstructive airway diseases, - bemrist breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
atectura breezhaler
novartis europharm limited - indacaterol acetate, mometasone furoate - asthma - drugs for obstructive airway diseases, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
zimbus breezhaler
novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - asthma - drugs for obstructive airway diseases, - maintenance treatment of asthma in adults whose disease is not adequately controlled.
seffalair spiromax
teva b.v. - fluticasone propionate, salmeterol xinafoate - asthma - drugs for obstructive airway diseases, - seffalair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.
bropair spiromax
teva b.v. - salmeterol xinafoate, fluticasone propionate - asthma - drugs for obstructive airway diseases, - bropair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.
vyvgart
argenx - efgartigimod alfa - myasthenia gravis - immunosuppressants - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.
tezspire
astrazeneca ab - tezepelumab - asthma - drugs for obstructive airway diseases, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
aerivio spiromax
teva b.v. - salmeterol xinafoate, fluticasone propionate - pulmonary disease, chronic obstructive; asthma - drugs for obstructive airway diseases, - aerivio spiromax is indicated for use in adults aged 18 years and older only.asthmaaerivio spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:patients not adequately controlled on a lower strength corticosteroid combination product orpatients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist.chronic obstructive pulmonary disease (copd)aerivio spiromax is indicated for the symptomatic treatment of patients with copd, with a fev1
airexar spiromax
teva b.v. - salmeterol, fluticasone propionate - pulmonary disease, chronic obstructive; asthma - drugs for obstructive airway diseases, - airexar spiromax is indicated for use in adults aged 18 years and older only.asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist.chronic obstructive pulmonary disease (copd)airexar spiromax is indicated for the symptomatic treatment of patients with copd, with a fev1
budesonide/formoterol teva
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - drugs for obstructive airway diseases, - budesonide/formoterol teva is indicated in adults 18 years of age and older only.asthmabudesonide/formoterol teva is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.orin patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.copdsymptomatic treatment of patients with severe copd (fev1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.